A role for proteinase-activated receptor 2 and PKC-ε in thrombin-mediated induction of decay-accelerating factor on human endothelial cells
Open Access
- 1 December 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 289 (6) , C1437-C1447
- https://doi.org/10.1152/ajpcell.00502.2004
Abstract
Thrombin, an important mediator of thrombosis and inflammation, may also enhance vascular cytoprotection. Thus thrombin induces expression of the complement-inhibitory protein decay-accelerating factor (DAF) in human umbilical vein endothelial cells (HUVECs), thus increasing protection against complement-mediated injury. Using PKC isozyme-specific peptide antagonists and adenoviral constructs, we have shown in the present study that PKC-ε is the primary isozyme involved in DAF induction by thrombin. Experiments with proteinase-activated receptor-1 (PAR1) and PAR2activating peptides (APs) showed that DAF expression induced by PAR1-AP was PKC-α-dependent; in contrast, PAR2-AP induction of DAF required activation of PKC-ε. PAR1-AP and PAR2-AP in combination exerted an additive effect on DAF protein expression, which was equivalent to that observed with thrombin alone. These data implied a specific role for PAR2in DAF induction, which was supported by the observation that upregulation of endothelial cell (EC) PAR2-enhanced DAF induction by thrombin. ERK1/2, p38, and JNK MAPK were also involved in thrombin-induced DAF upregulation, with evidence of interdependence between ERK1/2 and JNK. A role for transactivation of PAR2by PAR1was suggested by partial inhibition of thrombin-induced DAF expression by the PAR1signaling antagonists BMS-200261 and SCH79797 , whereas inhibition of thrombin-induced cleavage of PAR1by specific MAbs or hirudin completely abrogated the response. Together, these data imply that the predominant pathway for thrombin-induced DAF expression involves transactivation of PAR2by PAR1and signaling via PKC-ε/MAPK. This may represent an important, novel pathway for endothelial cytoprotection during inflammation and angiogenesis and suggests that PAR2may play a central role in some thrombin-induced responses.Keywords
This publication has 66 references indexed in Scilit:
- Protease-activated Receptor-1 Activation of Endothelial Cells Induces Protein Kinase Cα-dependent Phosphorylation of Syntaxin 4 and Munc18cJournal of Biological Chemistry, 2005
- Modulation of visceral pain and inflammation by protease‐activated receptorsBritish Journal of Pharmacology, 2004
- Differential Expression of Protease-Activated Receptors 1, 2, and 4 on Human Endothelial Cells from Different Vascular SitesPathobiology, 2003
- Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1Biochemical Journal, 2003
- Proinflammatory role of proteinase‐activated receptor‐2 in humans and mice during cutaneous inflammation in vivoThe FASEB Journal, 2003
- Modulation of Rho GTPase activity in endothelial cells by selective proteinase-activated receptor (PAR) agonistsJournal of Thrombosis and Haemostasis, 2003
- Differential Actions of PAR 2 and PAR 1 in Stimulating Human Endothelial Cell Exocytosis and PermeabilityCirculation Research, 2003
- A Protective Role of PKCϵ against TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis in Glioma CellsBiochemical and Biophysical Research Communications, 2001
- Immunohistochemical Colocalization of the Terminal Complex of Human Complement and Smooth Muscle Cell α-Actin in Early Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Thrombin-Mediated Increase in Vascular Endothelial PermeabilitySeminars in Thrombosis and Hemostasis, 1992